• Overview
  Quotes Prices Key Stats News Press Releases Sentiment
• Charts
  Chart Technicals
• Company
  Splits Dividends Recommendations Price Target Insider Trades Holders Peers Filings Notes due Fail to deliver ESG Score Executive Compensation Profile
• Earnings
  Price Reaction Earnings Estimates Trends Call Transcripts
• Financials
  Fundamentals DCF Beta
• Analysis
  Up/Down Intra-day Events Performance Recovery Returns Price Distribution Unusual Volume Best Days Data Correlations Seasonality Volatility Trader Stats

Summary

News

09/06 09:20 EST - businesswire.com
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone payments and a 9% royalty on worldwide net sales of FILSPARI. FILSPARI was granted accelerated approval in.

08/30 04:04 EST - globenewswire.com
CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Global CD40 Ligand Market by Type (Monoclonal Antibody, Polyclonal Antibody), Application (Autoimmune Disease Treatment, Immunotherapy, Vaccine Development), End-Users - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering. The CD40 Ligand Market size was estimated at USD 697.21 million in 2023, USD 734.50 million in 2024, and is expected to grow at a CAGR of 5.47% to reachUSD 1.01 billion by 2030. This makes it intensely relevant in developing treatments for immune disorders, specific cancers, and autoimmune diseases. In therapeutic applications, CD40L-based treatments are crucial for managing conditions such as lymphoma and leukemia, potentially extending to some solid tumors by boosting the immune system's ability to fight cancer cells. Furthermore, CD40L's function in autoimmune disorders suggests its modulation could lessen disease severity in ailments such as systemic lupus erythematosus and rheumatoid arthritis. In vaccine development, enhancing immune responses through CD40L could significantly improve vaccine efficacy against various diseases.

08/06 22:58 EST - seekingalpha.com
Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Todd Davis - CEO Tavo Espinoza - CFO Paul Hadden - Senior Vice President of Investments and Business Development Karen Reeves - Senior Vice President of Investments and Head of Clinical Strategy Conference Call Participants Matt Hewitt - Craig-Hallum Douglas Miehm - RBC Capital Markets Lawrence Solow - CJS Operator Thank you for standing by. My name is Pam and I will be your conference operator today.

07/29 14:43 EST - seekingalpha.com
Ligand Pharmaceuticals: Solid Performer Performing Solidly
Ligand Pharmaceuticals has seen over a 50% increase in share value since its Q1 earnings report. Recent positive developments include new deals, regulatory successes, and raising 2024 guidance. A new deal of close to $200 million with Agenus and $100 million acquisition of APEIRON contribute to the positive outlook.

07/23 16:01 EST - businesswire.com
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date: Tuesday, August 6, 2024 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Conf.

07/10 09:01 EST - marketbeat.com
5 Best Short-Term Stocks to Consider Investing In
Not every investor is in the market for the long haul. Some prefer short time frames and volatile stocks, looking to make a profit in days or weeks rather than years.

07/08 07:00 EST - businesswire.com
Ligand to Acquire APEIRON Biologics AG for $100 Million
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA® (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $100 million in cash. In addition, Ligand will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain.

06/27 08:00 EST - businesswire.com
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration (FDA) for Ohtuvayre™ (ensifentrine). Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients in more than 20 years. Ligand has earned a $5.8 million milestone payment upon FDA ap.

06/18 08:00 EST - businesswire.com
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as MSD outside the United States and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE™, previously known as V116, a 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population. The indication for pneumococcal pneumonia is under accelerat.

06/14 13:01 EST - zacks.com
What Makes Ligand (LGND) a New Strong Buy Stock
Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

06/06 12:35 EST - zacks.com
Why Is Ligand (LGND) Up 4% Since Last Earnings Report?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

06/06 07:56 EST - zacks.com
New Strong Buy Stocks for June 6th
HWM, LGND, MATX, SMFKY and HAE have been added to the Zacks Rank #1 (Strong Buy) List on June 6, 2024.

06/04 10:56 EST - zacks.com
Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 32.3% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

06/04 09:52 EST - zacks.com
Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why
Ligand (LGND) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

05/23 16:59 EST - businesswire.com
Ligand to Participate in Upcoming Investor Conferences
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences: Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 29, 2024. Goldman Sachs Global Healthcare Conference (Miami). Management will present on June 12, 2024 at 4:00 p.m. ET. Managemen.

05/20 06:00 EST - investorplace.com
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off.

05/20 00:00 EST - https://www.zacks.com
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Gilead Sciences, Inc. (GILD Quick QuoteGILD - Free Report) announced positive interim results from the ongoing ASSURE study on pipeline candidate seladelpar.ASSURE is an open-label study evaluating the long-term safety and efficacy of seladelpar, a once-daily potent and selective peroxisome proliferator-activated receptor (PPAR) delta agonist or delpar.Seladelpar is a first-in-class oral, selective PPAR-delta agonist or delpar is being evaluated for treating primary biliary cholangitis (PBC).The study enrolled adult patients with PBC who previously participated in a study of seladelpar where a key eligibility criterion included an inadequate response or intolerance to ursodeoxycholic acid (UDCA). Most patients enrolled in ASSURE were female (94%), with a mean age of 59 years.PBC is a rare, chronic, cholestatic liver disease mainly affecting women.We remind investors that the candidate was added to Gilead’s pipeline following the recent acquisition of CymaBay Therapeutics, Inc. The interim results showed that treatment with seladelpar led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with PBC.This analysis did not include patients from the late-stage RESPONSE study, which will be reported separately.The study also evaluated several prespecified biochemical endpoints, including the composite response of alkaline phosphatase (ALP) below 1.67 x upper limit of normal (ULN), a decline in ALP of at least 15% and total bilirubin (TB) below the ULN.70% of patients receiving seladelpar 10mg achieved the clinically meaningful composite endpoint and 37% achieved ALP normalization at 12 months.The reduction in patient-reported pruritus was rapid and durable in patients with moderate to severe symptoms.Please note that a new drug application (NDA) for seladelpar for the treatment of PBC, including pruritus, in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to UDCA is under review in the United States.The FDA granted priority review to the NDA and set a target action date of Aug 14, 2024. The candidate is also under review in Europe.Seladelpar received FDA Breakthrough Therapy Designation for the treatment of PBC, including pruritus in patients without cirrhosis or with compensated cirrhosis and PRIME status (EMA) and Orphan Drug Designation in the United States and Europe for treating patients with PBC.Gilead’s shares have lost 16.4% year to date compared with the industry's decline of 5%. Image Source: Zacks Investment ResearchLast month, GILD reported better-than-expected results for the first quarter of 2024 as its loss was narrower than expected and sales beat estimates.Gilead Sciences, Inc. Price, Consensus and EPS Surprise Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote The company intends to expand its portfolio beyond the HIV franchise. The acquisition of CymaBay complements Gilead’s existing liver portfolio and a potential approval of seladelpar for PBC will strengthen this franchise.Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) received accelerated approval from the FDA in 2016 for the treatment of adult patients living with PBC without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, either in combination with UDCA with an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA.Zacks Rank & Stocks to ConsiderGilead currently carries a Zacks Rank #5 (Strong Sell).A couple of better-ranked stocks from the healthcare industry are Ligand Pharmaceuticals (LGND Quick QuoteLGND - Free Report) and ANI Pharmaceuticals (ANIP Quick QuoteANIP - Free Report) . Both stocks carry a Zacks Rank #2 (Buy). In the past 30 days, the Zacks Consensus Estimate for Ligand’s 2024 and 2025 earnings per share (EPS) has remained constant at $4.56 and $5.27, respectively. Shares of LGND are up 20.5% year to date.In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 EPS have improved from $4.43 to $4.44. Shares of ANIP have jumped 11.4% year to date. ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an earnings surprise of 53.90%, on average. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>

05/13 13:01 EST - zacks.com
Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade
Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

05/10 09:51 EST - zacks.com
Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why
Ligand (LGND) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

05/09 10:47 EST - zacks.com
Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
Here is how Ligand Pharmaceuticals (LGND) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.